Biomea Fusion, Inc. (BMEA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$45.1M
Cash & Equivalents
$11.7M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$95M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase2 Readout | — |
| 2027-06-01 | Phase2 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07502508 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While U... | PHASE2 | Recruiting | 60 |
| NCT07502495 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets | PHASE2 | Recruiting | 60 |
| NCT07223216 | Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants | PHASE1 | Active Not Recruiting | 80 |
| NCT05918692 | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | PHASE1 | Active Not Recruiting | 35 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.